BackgroundThe BRAFV600E mutation, which accounts for about 60–80% papillary thyroid carcinoma(PTC), has been identifiedas a prognostic marker for risk stratification of PTC patients. However, the BRAFV600E mutation as a prognostic marker in papillary thyroid microcarcinoma (PTMC) is unclear.MethodsWe performed a retrospective review of 101 patients who underwent surgery for PTMC. We studied the prevalence of the BRAFV600E mutation. The associations between the BRAFV600E mutation and clinicopathologic characteristics were analyzed.ResultsThe BRAFV600E mutation was observed in 72 patients (71.3%). There was no statistically significant correlation in age, gender, multifocality, extrathyroidal extension, presence of Hashimoto thyroiditis, and lymph node metastasis between the BRAFV600E mutant group and wild group.ConclusionsThe BRAFV600E mutation is not significantly associated with prognostic factors in PTMC.

No abstract

No abstract

모든 소아암 중 갑상선암의 유병률은 0.5%에서 3.0%를 차 지한다. 1) 그 중 갑상선 분화암은 조직학적으로 갑상선 유두상 암종(papillary thyroid carcinoma), 갑상선 여포상 암종(follicular thyroid carcinoma), Hu ¨rthle 세포 암종(Hu ¨rthle cell carcinoma) 등이며, 갑상선 분화암 중에서 소아와 청소년은 2.6~ 12.9%를 차지하며, 소아와 청소년에서는 가장 흔한 내분비 암 종이다. 2) 대부분 11세에서 17세 사이에 발생하며, 5세 이하에서 는 드물게 발생한다. 1)

No abstract